India's NPPA wants laggard drug firms to register; MabSpace, Hengrui partner on novel antibody targets;

> Nearly one-third of the top 100 pharmaceutical companies have not yet responded to an order from India's National Pharmaceutical Pricing Authority to register products on an online database. Report

> Hong Kong-based MabSpace Biosciences and China's Jiangsu Hengrui Medicine announced plans to co-develop novel antibody therapeutics on two unspecified targets. Release

> South Korea's Kolon Group said that its Invossa allogeneic cell therapy candidate for osteoarthritis of the knee received U.S. FDA approval for Phase III clinical trials, marking the first such potential treatment to reach that stage in the world. Report

> On May 20, Japan's Eisai launched an in-house developed novel anticancer agent Lenvima Capsule 4 mg and 10 mg (lenvatinib mesylate) as a treatment for unresectable thyroid cancer. Report